And typically, when something is covered by public insurance programs, private payers eventually follow suit
[,] Some GLP-1, such as liraglutide and exenatide, have shown potential outcomes in non-pregnant populations for improving blood glucose levels and promoting weight loss, making them a potentially appealing option for GDM
In particular, it allocated some of the marketing teams, academic resources and sales channels originally used for dulaglutide to tirzepatide, helping it quickly enter the market and gain a foothold in the GLP - 1 field
Do not attempt to return to the original calendar
GLP-1s are powerful appetite suppressants, and for individuals with a history of restriction, bingeing, purging, or body image struggles, they can be destabilizing